Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Yun Shao

Showing results (41-50 of 114) with videos related to

Pageof 12
Sort By:
Oncology|October 12, 2011
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapyYu-Yun Shao, Zhong-Zhe Lin, Te-Jung Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 SuppressionChiun Hsu, Liang-In Lin, Yu-Che Cheng, et al.
BMC Cancer|January 12, 2022
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching studySan-Chi Chen, Yi-Hsiang Huang, Ming-Huang Chen, et al.
Japanese Journal of Clinical Oncology|October 6, 2017
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinomaYu-Yun Shao, Hang Lin, Yong-Shi Li, et al.
British Journal of Cancer|August 9, 2017
Right or left? Side selection for a totally implantable vascular access device: a randomised observational studyWen-Ying Lin, Chih-Peng Lin, Chih-Hung Hsu, et al.
Anticancer Research|November 17, 2012
Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinomaYu-Yun Shao, Chi-Long Chen, Ming-Chih Ho, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2012
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancerYu-Yun Shao, Wen-Yi Shau, Zhong-Zhe Lin, et al.
Esophagus : Official Journal of the Japan Esophageal Society|November 10, 2025
Does chemotherapy regimen matter for first-line immunochemotherapy in low PD-L1-expressing esophageal squamous cell carcinoma? A systemic review and meta-analysisJhe-Cyuan Guo, Pei-Shan Lin, Wen-Yi Shau, et al.
Molecular & Cellular Proteomics : MCP|April 9, 2015
Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver CancerChao-Chi Yeh, Chih-Hung Hsu, Yu-Yun Shao, et al.
Acta Anaesthesiologica Taiwanica : Official Journal of the Taiwan Society of Anesthesiologists|June 19, 2016
Key opioid prescription concerns in cancer patients: A nationwide studyChih-Peng Lin, Chih-Hung Hsu, Wen-Mei Fu, et al.
Pageof 12

Showing results (41-50 of 114) with videos related to

Sort By:
Pageof 12
Oncology|October 12, 2011
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapyYu-Yun Shao, Zhong-Zhe Lin, Te-Jung Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 SuppressionChiun Hsu, Liang-In Lin, Yu-Che Cheng, et al.
BMC Cancer|January 12, 2022
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching studySan-Chi Chen, Yi-Hsiang Huang, Ming-Huang Chen, et al.
Japanese Journal of Clinical Oncology|October 6, 2017
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinomaYu-Yun Shao, Hang Lin, Yong-Shi Li, et al.
British Journal of Cancer|August 9, 2017
Right or left? Side selection for a totally implantable vascular access device: a randomised observational studyWen-Ying Lin, Chih-Peng Lin, Chih-Hung Hsu, et al.
Anticancer Research|November 17, 2012
Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinomaYu-Yun Shao, Chi-Long Chen, Ming-Chih Ho, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2012
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancerYu-Yun Shao, Wen-Yi Shau, Zhong-Zhe Lin, et al.
Esophagus : Official Journal of the Japan Esophageal Society|November 10, 2025
Does chemotherapy regimen matter for first-line immunochemotherapy in low PD-L1-expressing esophageal squamous cell carcinoma? A systemic review and meta-analysisJhe-Cyuan Guo, Pei-Shan Lin, Wen-Yi Shau, et al.
Molecular & Cellular Proteomics : MCP|April 9, 2015
Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver CancerChao-Chi Yeh, Chih-Hung Hsu, Yu-Yun Shao, et al.
Acta Anaesthesiologica Taiwanica : Official Journal of the Taiwan Society of Anesthesiologists|June 19, 2016
Key opioid prescription concerns in cancer patients: A nationwide studyChih-Peng Lin, Chih-Hung Hsu, Wen-Mei Fu, et al.
Pageof 12